PG
Peter Greenleaf
Director

Peter Greenleaf insider trades: Pelthos Therapeutics (PTHS) stock buys and sales

Director, Pelthos Therapeutics Last trade Oct 2, 2026 61 Form 4 filings
$54K
Sold, last 12 months
3 sales
$0
Bought, last 12 months
0 buys
10
Open-market trades
since 2016
11
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Peter reports to the SEC

and 5 more companies

Open-market buys and sales

10 trades reported on SEC Form 4, newest first

DateStockTypeValue
Oct 2, 2026PTHS↓ Sell$17K
Jul 2, 2026PTHS↓ Sell$21K
Apr 2, 2026PTHS↓ Sell$17K
Mar 4, 2025AUPH↓ Sell$2.9M
Mar 6, 2024AUPH↓ Sell$711K
Mar 2, 2023AUPH↓ Sell$293K
Mar 2, 2022AUPH↓ Sell$109K
May 11, 2021AUPH↑ Buy$55K
May 18, 2018CERC↑ Buy$50K
Nov 29, 2016SCMP↓ Sell$3.4M

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other PTHS insiders

Open-market trades in the last 12 months

About Peter Greenleaf's insider trades

Peter Greenleaf is a director at Pelthos Therapeutics (PTHS). Since Nov 29, 2016, Peter has reported 2 open-market purchases worth $105K and 8 sales worth $7.4M on SEC Form 4. In the last 12 months: 3 sales ($54K).

Their filings also include grants and awards (43 filings), option exercises (7 filings), shares returned to the company (5 filings), shares withheld for taxes (3 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every PTHS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.